| Strategies for Dodging the Obstacles in CAR T Cell Therapy P Safarzadeh Kozani, P Safarzadeh Kozani, F Rahbarizadeh, ... Frontiers in Oncology 11, 924, 2021 | 45 | 2021 |
| Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti … SK Nikkhoi, F Rahbarizadeh, D Ahmadvand, SM Moghimi European journal of pharmaceutical sciences 122, 42-50, 2018 | 33 | 2018 |
| Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin A Farasat, F Rahbarizadeh, D Ahmadvand, S Ranjbar, ... Journal of liposome research 29 (1), 53-65, 2019 | 30 | 2019 |
| Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targeting SK Nikkhoi, F Rahbarizadeh, S Ranjbar, S Khaleghi, A Farasat Molecular immunology 96, 98-109, 2018 | 28 | 2018 |
| Oligo-clonal nanobodies as an innovative targeting agent for cancer therapy: new biology and novel targeting systems SK Nikkhoi, F Rahbarizadeh, D Ahmadvand Protein expression and purification 129, 115-121, 2017 | 18 | 2017 |
| Bispecific killer cell engager with high affinity and specificity toward CD16a on NK cells for cancer immunotherapy SK Nikkhoi, G Li, S Eleya, G Yang, VG Vandavasi, A Hatefi Frontiers in immunology 13, 1039969, 2023 | 17 | 2023 |
| Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells N Paydarnia, S Khoshtinat Nikkhoi, A Fakhravar, M Mehdiabdol, ... Molecular biology reports 46, 3129-3140, 2019 | 14 | 2019 |
| Gadolinium-labeled affibody-XTEN recombinant vector for detection of HER2+ lesions of ovarian cancer lung metastasis using quantitative MRI A Nomani, G Li, S Yousefi, S Wu, OM Malekshah, SK Nikkhoi, M Pourfathi, ... Journal of Controlled Release 337, 132-143, 2021 | 10 | 2021 |
| Synergistic effect of expressed miR-128 and Puma protein on targeted induction of tumor cell apoptosis SK Nikkhoi, R Dorostkar, S Ranjbar, H Heydarzadeh, M Tat, M Ghalavand, ... Iranian Journal of Biotechnology 14 (3), 185, 2016 | 9 | 2016 |
| Isolation and characterization of human anti-CD20 single-chain variable fragment (scFv) from a Naive human scFv library N Shams, S Khoshtinat Nikkhoi, Z Gu, F Rahbarizadeh Medical Oncology 39 (11), 177, 2022 | 6 | 2022 |
| The evaluation and comparison of transcriptionally targeted noxa and puma killer genes to initiate apoptosis under cancer-specific promoter cxcr1 in hepatocarcinoma gene therapy SK Nikkhoi, H Heydarzadeh, S Ranjbar, F Salimi, M Aghaeifard, ... Hepatitis monthly 16 (10), 2016 | 6 | 2016 |
| Stem cell-assisted enzyme/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands G Li, SK Nikkhoi, A Hatefi Medical Oncology 40 (4), 110, 2023 | 5 | 2023 |
| Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells SR Banihashemi, F Rahbarizadeh, AZ Hosseini, D Ahmadvand, ... International Immunopharmacology 100, 107927, 2021 | 5 | 2021 |
| Rutgers SK Nikkhoi The State University of New Jersey, United States, 0 | 5 | |
| Camelid Single-Domain Antibodies for Targeting Cancer Nanotheranostics S Khaleghi, S Khoshtinat Nikkhoi, F Rahbarizadeh Cancer Nanotheranostics: Volume 1, 93-123, 2021 | 3 | 2021 |
| Anti-HER2 VHH Targeted Fluorescent Liposome as Bimodal Nanoparticle for Drug Delivery and Optical Imaging. S Khaleghi, F Rahbarizadeh, SK Nikkhoi Recent Patents on Anti-cancer Drug Discovery 16 (4), 552-562, 2021 | 2 | 2021 |
| A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab’s epitope with versatile biochemical, biological, and medical applications SK Nikkhoi, H Heydarzadeh, VG Vandavasi, G Yang, P Louro, M Polunas, ... Immunologic Research 72 (1), 103-118, 2024 | 1 | 2024 |
| SINGLE-DOMAIN HIGH AFFINITY ANTIBODIES AND METHODS OF USE THEREOF A Hatefi, S Khoshtinat Nikkhoi WO Patent WO/2023/129,819, 2023 | 1 | 2023 |
| Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice SK Nikkhoi, G Yang, H Owji, M Grizotte-Lake, RI Cohen, LG Gonzalez, ... Journal for ImmunoTherapy of Cancer 12 (3), 2024 | | 2024 |
| Design, Engineering, and Characterization of a Bispecific Killer Cell Engager With High Affinity and Specificity Toward CD16a Receptor on Natural Killer Cells for Cancer … SK Nikkhoi Rutgers The State University of New Jersey, School of Graduate Studies, 2023 | | 2023 |
Alireza FarasatAssistant professorVerified email at avicenna.ac.ir
